

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 08:58:33 ON 25 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JAN 2006 HIGHEST RN 872490-64-7
DICTIONARY FILE UPDATES: 23 JAN 2006 HIGHEST RN 872490-64-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10813426\3.str



chain nodes :
10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 39 40 41
44 45 46 47 48
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25
chain bonds :
1-41 2-40 3-14 4-39 7-38 8-10 9-44 10-11 10-12 12-13 14-15 14-47 14-48
15-16 15-45 15-46 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25
exact/norm bonds :
1-41 2-40 4-39 5-7 6-9 7-8 7-38 8-9 9-44 10-11 10-12 12-13 14-47 14-48
15-16 15-45 15-46 16-17 16-34 18-19 19-33 26-31 27-28 28-32
exact bonds :
3-14 8-10 14-15 17-18 18-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 20 :

G1:H,CH3

G2:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS
39:CLASS 40:CLASS 41:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 08:59:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 80161 TO ITERATE

100.0% PROCESSED 80161 ITERATIONS
SEARCH TIME: 00.00.10

L2 54 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

54 ANSWERS

FULL ESTIMATED COST

166.94

167.57

FILE 'CAPLUS' ENTERED AT 08:59:16 ON 25 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 24 Jan 2006 (20060124/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2
L3 3 L2

=> d ibib abs hitstr 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:772649 CAPLUS

DOCUMENT NUMBER: 141:277468

TITLE:

Preparation and in vitro activity of novel indole-2-carboxamide β 2-adrenoreceptor agonists
Brown, Alan D.; Bryans, Justin; Bunnage, Mark E.;
Glossop, Paul; Lane, Charlotte; Mantell, Simon;
Lewthwaite, Russell A.

PATENT ASSIGNEE(S):

Pfizer Limited, UK

SOURCE:

Eur. Pat. Appl., 58 pp.

DOCUMENT TYPE:

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1460064	A1	20040922	EP 2003-100650	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2517569	AA	20040923	CA 2004-2517569	20040301
WO 2004080964	A1	20040923	WO 2004-IB591	20040301
WO 2004080964	C1	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1611097	A1	20060104	EP 2004-715968	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2004235833	A1	20041125	US 2004-800253	20040312
PRIORITY APPLN. INFO.:			EP 2003-100650	A 20030314
			US 2003-486535P	P 20030710
			WO 2004-IB591	W 20040301


OTHER SOURCE(S):

MARPAT 141:277468

GI

Instant App

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. [I, Q = single bond or C1-4-alkyl-substituted C1-4 carbon chain; R1 = H, C1-4 alkyl; R2 = H, alkyl or benzyl (un)substituted by OH, C1-6 (hydroxy)alkyl, C1-6 alkoxy, halo, OCF3, substituted alkylsulfonfylamino, SO2NR9R10, CF3, NR9R10 (R9, R10 = H, C1-4-alkyl); R3 =

H, C1-6 (hydroxy)alkyl; A = C3-6(hydroxy) (alkyl)cycloalkyl, C5-10 alkyl

or (alkyl)amino (un)substituted heterocyclyl, containing 1-3 O, S, N

heteroatoms:

Ph (un)substituted by OCF3, alkylsulfonfylamino, SO2NR9R10, NR9R10, OCHH2Ph, OH, C1-6 (hydroxy)alkyl, C1-6 alkoxy, halo, thio(C1-6)alkyl, CF3,

same R9, R10; preferably R1 = Me; R2 = H, Me, Et, CH2Ph; R3 = H, Me; Q = CH2, CH2CH2, CHMe; A = pyridyl, thiazolyl; preferably 18 specific

compds. corresponding to the above definitions), useful as β 2-adrenoreceptor agonists (cAMP EC50 = 0.03-0.75 nM), and their pharmaceutically

acceptable

acid or base salts, are claimed. Also claimed are an intermediate carboxylic acid and ester, corresponding to definition I and process of preparation of compds. I, comprising coupling of the carboxylic acid with amines R3NHQA (same R3, Q, A). The use of compds. I is claimed for treatment of airway diseases, such as asthma, bronchitis, pneumonia, emphysema, dyspnea, airways hyper-reactivity, pneumoconiosis; central nervous system disorders such as depression, Alzheimer's disease, Parkinson's disease, mental impairment, drug dependence, dementia; premature labor; allergic skin diseases, psoriasis, glaucoma, gastric and peptic ulceration. In an example, O-tert-butylidimethylsilyl derivative of the

(R,R)-5-substituted indole-2-carboxylic acid, corresponding to definition I (R1 = Me, R2 = H), prepared by N-alkylation of Me

(2'R)-5-(2-aminopropyl)-1H-indole-2-carboxylate by (aR)-4-PhCH2O-3-HOCH2C6H3CH(OTBDMS)CH2Br, was reacted with 2-CF3O-C6H4NH2 to give, after deprotection, (R,R)-I, (Q

= CH2, A = 2-CF3O-C6H4, R1 = Me, R2 = H).

IT 757963-27-2P 757963-30-7P 757963-33-0P

757963-36-3P 757963-39-6P 757963-41-0P

757963-44-3P 757963-47-6P 757963-50-1P

757963-53-4P 757963-56-7P 757963-59-0P

757963-61-4P 757963-63-6P 757963-65-8P

757963-67-0P 757963-69-2P 757963-71-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-aminoalkyl-substituted 2-indole-N-alkylcarboxamides as β 2-adrenoreceptor agonists)

RN 757963-27-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(1S)-1-phenylethyl]- (trifluoromethoxy)phenylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 757963-30-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 757963-33-0 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(1S)-1-phenylethyl]- (trifluoromethoxy)phenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

CF3

RN 757963-36-3 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 757963-39-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-(cyclopropylmethyl)-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 757963-41-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 757963-44-3 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 757963-47-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-(cyclobutylmethyl)-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 757963-56-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(4-(methylamino)sulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


NHMe

RN 757963-59-0 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(4-(aminosulfonyl)phenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 757963-50-1 CAPLUS
 CN 1H-Indole-2-carboxamide, N-(cyclopentylmethyl)-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 757963-53-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-(cyclohexylmethyl)-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

NH2

RN 757963-61-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 757963-63-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(1R)-1-phenylethyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 757963-65-8 CAPLUS
CN 1H-Indole-2-carboxamide,
1-ethyl-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(1R)-1-phenylethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 757963-67-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-1-methyl-N-[(1R)-1-phenylethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 757963-69-2 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI)
(CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:333571 CAPLUS
DOCUMENT NUMBER: 140:321235
TITLE: Preparation of indolecarboxamides as β 2 adrenergic receptor agonists
INVENTOR(S): Brown, Alan Daniel; Bryans, Justin Stephen; Bunnage, Mark Edward; Glossop, Paul Alan; Lane, Charlotte
Alice Louise; Lewthwaite, Russell Andrew; Mantell, Simon John
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


Inventors

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032921	A1	20040422	WO 2003-1B4441	20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1407769	A1	20040414	EP 2002-292513	20021011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
EP 1440966	A1	20040728	EP 2003-290069	20031011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2499314	AA	20040422	CA 2003-2499314	20031006
EP 1556034	A1	20050727	EP 2003-751095	20031006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015234	A	20050823	BR 2003-15234	20031006
NO 2005001406	A	20050422	NO 2005-1406	20050317
PRIORITY APPL. INFO.:			EP 2002-292513	A 20021011
			EP 2003-290069	A 20031011
			WO 2003-1B4441	W 20031006

OTHER SOURCE(S): MARPAT 140:321235
G1


L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 757963-71-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]butyl]-N-[(1R)-1-phenylethyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. (I: n = 0-4; R1, R2 = H, alkyl; R3 = H, (un)substituted alkyl; R4-R8 = H, OH, alkyl, alkoxy, hydroxyalkyl, thioalkyl, halo, trifluoromethyl, benzyloxy; their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations), were prepared as β 2 adrenergic receptor agonists. Thus, 5-[(2R)-2-[(2R)-2-[(tert-butyl)dimethylsilyloxy]-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-1H-indole-2-carboxylic acid (preparation given) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole, and 2-methoxybenzylamine were stirred 18 h in DMF to give the silyl-protected amide derivative. This was stirred with NH4F in MeOH/H2O to give 5-[(2R)-2-[(2R)-2-[(tert-butyl)dimethylsilyloxy]-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide. 1 showed a β 2 cAMP EC50 = 0.02-4 nM. 1 are useful for treating inflammatory, allergic and respiratory diseases.


IT 679427-60-2P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-(4-benzyloxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β 2 adrenergic receptor agonist; preparation of indolecarboxamides as β 2 adrenergic receptor agonists)

RN 679427-60-2 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(2,6-dimethoxy-4-(phenylmethoxy)phenyl)methyl]-
5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



IT 677026-80-1P 677026-81-2P 677026-82-3P
677026-83-4P 677026-84-5P 679427-58-8P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dichlorobenzyl)-1H-indole-2-carboxamide 679427-59-8P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-

hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-61-3P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-62-4P 679427-63-5P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-hydroxy-6-methoxybenzyl)-1H-indole-2-carboxamide 679427-64-6P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-difluorobenzyl)-1H-indole-2-carboxamide 679427-65-7P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-chlorobenzyl)-1H-indole-2-carboxamide 679427-66-8P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-fluorobenzyl)-1H-indole-2-carboxamide 679427-67-9P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxybenzyl)-1H-indole-2-carboxamide 679427-68-0P

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxybenzyl)-1H-indole-2-carboxamide 679427-69-1P

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amin

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

olpropyl]-N-(2-methylsulfonylbenzyl)-1H-indole-2-carboxamide 679427-70-4P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-methylsulfonylbenzyl)-1H-indole-2-carboxamide 679427-71-5P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,3-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-72-6P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-73-7P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide 679427-74-8P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-N-methyl-1H-indole-2-carboxamide 679427-75-9P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-

(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-1H-indole-2-carboxamide 679427-76-0P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-fluorobenzyl)-1H-indole-2-carboxamide 679427-77-1P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxy-3-methylbenzyl)-1H-indole-2-carboxamide 679427-78-2P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-methoxy-2-methylbenzyl)-1H-indole-2-carboxamide 679427-79-3P, 1-Ethyl-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-

hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-80-6P, 1-Ethyl-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide 679427-81-7P, 1-Ethyl-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide 679427-82-8P, 1-Methyl-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-

hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-83-9P, 1-Methyl-5-[(2R)-2-[(2R)-2-Hydroxy-

2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide 679427-84-0P, 1-Methyl-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide 679427-85-1P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide 679427-86-2P,

5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-87-3P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide 679427-88-4P, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-benzyl-1H-indole-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(B2 adrenergic receptor agonist; prepn. of indolecarboxamides as B2 adrenergic receptor agonists)

RN 677026-80-1 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677026-81-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 677026-82-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 677026-83-4 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 677026-84-5 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(2-(3-methoxyphenyl)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 679427-58-8 CAPLUS
 CN 1H-Indole-2-carboxamide,
 N-[(2,4-dichlorophenyl)methyl]-5-[(2R)-2-[(2R)-2-
 hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-59-9 CAPLUS
 CN 1H-Indole-2-carboxamide,
 N-[(3-hydroxy-2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-
 [(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl
]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-hydroxy-6-
 methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-64-6 CAPLUS
 CN 1H-Indole-2-carboxamide,
 N-[(2,6-difluorophenyl)methyl]-5-[(2R)-2-[(2R)-2-
 hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-65-7 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(2-chlorophenyl)methyl]-5-[(2R)-2-[(2R)-2-
 hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-66-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(2-fluorophenyl)methyl]-5-[(2R)-2-[(2R)-2-
 hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 679427-61-3 CAPLUS
 CN 1H-Indole-2-carboxamide,
 N-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-
 [(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl
]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-62-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-
 (hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxy-6-
 phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679427-63-5 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-67-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-
 (hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(4-hydroxyphenyl)methyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-68-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-
 (hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(3-hydroxyphenyl)methyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679427-69-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-
 (hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methylthio)phenyl]methyl]-
 (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 679427-70-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(4-(methylthio)phenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe


RN 679427-71-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(2,3-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 679427-73-7 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(2-ethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-74-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-75-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679427-76-0 CAPLUS

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

OMe

RN 679427-72-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OMe


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-Indole-2-carboxamide, N-[(4-fluorophenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-77-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(2-methoxy-3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679427-78-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl]amino]propyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PAGE 1-B

—OMe

RN 679427-79-3 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(2,6-dimethoxyphenyl)methyl]-1-ethyl-5-[(2R)-2-


[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-80-6 CAPLUS
CN 1H-Indole-2-carboxamide,
1-ethyl-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-81-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-chlorophenyl)methyl]-1-ethyl-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-85-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-86-2 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679427-87-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2-ethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 679427-82-8 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-83-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679427-84-0 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-chlorophenyl)methyl]-5-[(2R)-2-[(2R)-2-


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-88-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:305136 CAPLUS
 DOCUMENT NUMBER: 140:303532
 TITLE: Preparation of indolecarboxamides as $\beta 2$ adrenergic receptor agonists
 INVENTOR(S): Brown, Alan; Bryans, Justin; Bunnage, Mark Edward; Glossop, Paul Alan; Lane, Charlotte; Mantell, Simon
 PATENT ASSIGNEE(S): Pfizer Limited, UK
 SOURCE: Eur. Pat. Appl., 32 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

Inventors

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1407769	A1	20040414	EP 2002-292513	20021011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2499314	AA	20040422	CA 2003-2499314	20031006
WO 2004032921	A1	20040422	WO 2003-1B4441	20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, BF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1356034	A1	20050727	EP 2003-751095	20031006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015234	A	20050823	BR 2003-15234	20031006
US 2004116503	A1	20040617	US 2003-684233	20031009
US 6844362	B2	20050118		
US 2005085526	A1	20050421	US 2004-959934	20041005
NO 2005001406	A	20050422	NO 2005-1406	20050317
PRIORITY APPLN. INFO.			EP 2002-292513	A 20021011
			US 2003-438639P	P 20030108
			EP 2003-290069	A 20030110
			WO 2003-1B4441	W 20031006
			US 2003-684233	A3 20031009

OTHER SOURCE(S): MARPAT 140:303532
 GI

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. (I; n = 0-4; R1, R2 = H, alkyl; R3 = H, alkyl, hydroxyalkyl; R4-R8 = H, OH, alkyl, alkoxy, hydroxyalkyl, thioalkyl, halo, trihalomethyl), were prepared Thus, 5-((2R)-2-((2R)-2-((tert-butyl)dimethylsilyloxy)-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-1H-indole-2-carboxylic acid (preparation given) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole, and 2-methoxybenzylamine were stirred 18 h in DMF to give the silyl-protected amide derivative This was stirred with NH4F in MeOH/H2O to give 5-((2R)-2-((2R)-2-((tert-butyl)dimethylsilyloxy)-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-N-(2-methoxybenzyl)-1H-indole-2-carboxamide. I showed a $\beta 2$ cAMP EC50 = 0.02-0.9 nM. The indole derivs. according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

IT 677026-80-1P 677026-81-2P 677026-82-3P
 677026-83-4P 677026-84-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of indolecarboxamides as $\beta 2$ adrenergic receptor agonists)
 RN 677026-80-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-((2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-N-((2-methoxyphenyl)methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 677026-81-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-((2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-N-((2-methoxyphenyl)methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CF3
 RN 677026-82-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-((2,6-dimethoxyphenyl)methyl)-5-((2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 677026-83-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-((2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-N-((2-methoxyphenyl)methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OMe
 RN 677026-84-5 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-((2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]propyl)-N-((2-(3-methoxyphenyl)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




=>

Uploading C:\Program Files\Stnexp\Queries\10813426\positional isomer 1.str



positional isomer



chain nodes :

10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 39 40 43
44 45 46 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 20 21 22 23 24 25

chain bonds :

1-40 2-39 3-48 4-14 7-38 8-10 9-43 10-11 10-12 12-13 14-15 14-47 14-46
15-16 15-44 15-45 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25

exact/norm bonds :

1-40 2-39 3-48 5-7 6-9 7-8 7-38 8-9 9-43 10-11 10-12 12-13 14-47 14-46
15-16 15-44 15-45 16-17 16-34 18-19 19-33 26-31 27-28 28-32

exact bonds :

4-14 8-10 14-15 17-18 18-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

G1:H,CH3

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS
 39:CLASS 40:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS

L4 STRUCTURE UPLOADED

=> s l4

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 09:01:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 195 TO ITERATE

100.0% PROCESSED 195 ITERATIONS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 3063 TO 4737
PROJECTED ANSWERS: 0 TO 0

0 ANSWERS

L5 0 SEA SSS SAM L4

L6 0 L5

=> s l4 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:01:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3846 TO ITERATE

100.0% PROCESSED 3846 ITERATIONS
SEARCH TIME: 00.00.01


L7 0 SEA SSS FUL L4

L8 0 L7

=>

Uploading C:\Program Files\Stnexp\Queries\10813426\positional isomer 2.str

0 ANSWERS



positional isomer



chain nodes :

10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 39 42 43
44 45 46 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 20 21 22 23 24 25

chain bonds :

1-39 2-14 3-47 4-48 7-38 8-10 9-42 10-11 10-12 12-13 14-15 14-46 14-45
15-16 15-43 15-44 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25

exact/norm bonds :

1-39 3-47 4-48 5-7 6-9 7-8 7-38 8-9 9-42 10-11 10-12 12-13 14-46 14-45
15-16 15-43 15-44 16-17 16-34 18-19 19-33 26-31 27-28 28-32

exact bonds :

2-14 8-10 14-15 17-18 18-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

G1:H,CH3

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS
39:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS

L9 STRUCTURE UPLOADED

=> s 19 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:02:22 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 81734 TO ITERATE

100.0% PROCESSED 81734 ITERATIONS
 SEARCH TIME: 00.00.11


0 ANSWERS

L10 0 SEA SSS FUL L9


L11 0 L10

=>

Uploading C:\Program Files\Stnexp\Queries\10813426\positional isomer 3.str



positional isomer



chain nodes :

10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 40 41 42
 43 44 45 46 47

ring nodes :

1 2 3 4 5 6 7 8 9 20 21 22 23 24 25

chain bonds :

1-14 2-47 3-45 4-46 7-38 8-10 9-40 10-11 10-12 12-13 14-15 14-44 14-43
 15-16 15-41 15-42 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
 24-25

exact/norm bonds :

2-47 3-45 4-46 5-7 6-9 7-8 7-38 8-9 9-40 10-11 10-12 12-13 14-44 14-43
15-16 15-41 15-42 16-17 16-34 18-19 19-33 26-31 27-28 28-32

exact bonds :

1-14 8-10 14-15 17-18 18-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

G1:H,CH3

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS

28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS

40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS

L12 STRUCTURE UPLOADED

=> s l12 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:03:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 144106 TO ITERATE

100.0% PROCESSED 144106 ITERATIONS
SEARCH TIME: 00.00.13


0 ANSWERS

L13 0 SEA SSS FUL L12

L14 0 L13

=>

Uploading C:\Program Files\Stnexp\Queries\10813426\positional isomer 4.str



positional isomer



chain nodes :

10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 39 40 41 42
43 44 45 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 20 21 22 23 24 25

chain bonds :

1-47 2-45 3-14 4-44 7-10 8-48 9-39 10-12 10-11 12-13 14-15 14-43 14-42
15-16 15-40 15-41 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25

exact/norm bonds :

1-47 2-45 4-44 5-7 6-9 7-8 8-9 8-48 9-39 10-12 10-11 12-13 14-43 14-42
15-16 15-40 15-41 16-17 16-34 18-19 19-33 26-31 27-28 28-32

exact bonds :

3-14 7-10 14-15 17-18 18-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

G1:H,CH3

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 39:CLASS
40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 47:CLASS 48:CLASS

L15 STRUCTURE UPLOADED

=> s l15 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:04:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 483 TO ITERATE

100.0% PROCESSED 483 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L16 0 SEA SSS FUL L15

L17 0 L16

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	855.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

STN INTERNATIONAL LOGOFF AT 09:05:05 ON 25 JAN 2006

0.21

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005.  A new display format, IDERL, is now
* available and contains the CA role and document type information.
*
*****
```



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

$$\Rightarrow$$

Uploading C:\Program Files\Stnexp\Queries\10813426\4.str



↙ Q can be a single bond

```

chain nodes :
10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 39 40 41
44 45 46 47 48 49
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25
chain bonds :
1-41 2-40 3-14 4-39 7-38 8-10 9-44 10-11 10-12 12-13 13-49 14-15 14-47
14-48 15-16 15-45 15-46 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28
28-32
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25
exact/norm bonds :
1-41 2-40 4-39 5-7 6-9 7-8 7-38 8-9 9-44 10-11 10-12 12-13 13-49 14-47
14-48 15-16 15-45 15-46 16-17 16-34 18-19 19-33 26-31 27-28 28-32
exact bonds :
3-14 8-10 14-15 17-18 18-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 20 :

```

G1:H,CH3

G2:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS
39:CLASS 40:CLASS 41:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS
49:Atom

```

L1 STRUCTURE UPLOADED

```

=> s l1 full
FULL SEARCH INITIATED 09:20:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 80161 TO ITERATE

```

```

100.0% PROCESSED 80161 ITERATIONS
SEARCH TIME: 00.00.11

```


54 ANSWERS

L2 54 SEA SSS FUL L1

```

=>
Uploading C:\Program Files\Stnexp\Queries\10813426\3.str

```



chain nodes :

10 11 12 13 14 15 16 17 18 19 26 27 28 31 32 33 34 38 39 40 41
44 45 46 47 48

ring nodes :

1 2 3 4 5 6 7 8 9 20 21 22 23 24 25

chain bonds :

1-41 2-40 3-14 4-39 7-38 8-10 9-44 10-11 10-12 12-13 14-15 14-47 14-48
15-16 15-45 15-46 16-17 16-34 17-18 18-19 18-20 19-33 26-31 27-28 28-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25

exact/norm bonds :

1-41 2-40 4-39 5-7 6-9 7-8 7-38 8-9 9-44 10-11 10-12 12-13 14-47 14-48
15-16 15-45 15-46 16-17 16-34 18-19 19-33 26-31 27-28 28-32

exact bonds :

3-14 8-10 14-15 17-18 18-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 20 :

G1:H,CH3

G2:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:CLASS
39:CLASS 40:CLASS 41:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS

L3 STRUCTURE UPLOADED

=> s 13 full

FULL SEARCH INITIATED 09:21:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 80161 TO ITERATE

100.0% PROCESSED 80161 ITERATIONS
SEARCH TIME: 00.00.10

54 ANSWERS

L4 54 SEA SSS FUL L3

=> s l2 or l4

L5 54 L2 OR L4

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

336.08

336.29

FILE 'CAPLUS' ENTERED AT 09:24:00 ON 25 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2006 VOL 144 ISS 5

FILE LAST UPDATED: 24 Jan 2006 (20060124/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2 or l4

3 L2

3 L4

L6

3 L2 OR L4

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.46

336.75

← crossed w/ original str.

} same hits - nothing new
when Q=0